Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone dose influence on ectopic lipids in hypopituitarism
NCT02360046Terminated
- Sponsor
- Insel Gruppe
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydrocortisone in secondary adrenal insufficiency (2 arms), sponsored by Insel Gruppe. Primary endpoints: Change from baseline in flexibility of Intramyocellular Lipids (IMCL) at 3 months and Change from baseline in flexibility of Intrahepatocellular Lipids (IHCL) at 3 months. Started Jan 2015; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
secondary adrenal insufficiency
Beyond the preview
Go deeper on NCT02360046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360046.